Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice

Inflamm Bowel Dis. 2022 Feb 1;28(2):318-321. doi: 10.1093/ibd/izab274.
No abstract available

Keywords: 5-ASA; COVID-19; Crohn’s disease; intestine; mucosal immunology.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme 2* / drug effects
  • Angiotensin-Converting Enzyme 2* / metabolism
  • Animals
  • COVID-19
  • Intestines* / drug effects
  • Intestines* / metabolism
  • Mesalamine* / pharmacology
  • Mice
  • SARS-CoV-2 / drug effects
  • Severity of Illness Index

Substances

  • Mesalamine
  • Angiotensin-Converting Enzyme 2